Unidade Local De Saude De Matosinhos E.P.E.

This site in Senhora Da Hora, Portugal is active across a broad oncology portfolio, with a strong focus on breast cancer, lung cancer, gastroesophageal cancer, urothelial cancer, and lymphoma. The studies are mainly designed to test new treatment options, compare them with current standards, and improve outcomes for people with advanced or hard-to-treat neoplasms.

• Research in non-small cell lung cancer, including biomarker-defined and metastatic disease
• Studies in breast cancer, especially hormone receptor-positive and HER2-positive subtypes
• Trials in gastroesophageal and head and neck cancers to evaluate new combinations and supportive strategies
• Investigations in hematologic malignancies such as diffuse large B-cell lymphoma and follicular lymphoma

Overall, the oncology program emphasizes better disease control, longer survival, and more personalized care through studies of targeted therapies, immunotherapy, and combination treatment approaches.

A substantial part of the research landscape at this hospital involves cardiovascular diseases, obesity, type 2 diabetes, chronic kidney disease, and related metabolic disorders. These trials aim to reduce major cardiovascular events, improve risk-factor control, and explore treatments that may protect the heart, kidneys, and metabolic health over time.

• Atherosclerotic cardiovascular disease and prevention of heart attack or stroke
• Obesity, overweight, and type 2 diabetes management
• Chronic kidney disease and reduction of kidney-related complications
• Heart failure and broader cardiometabolic risk reduction

The research focus includes testing new therapies and evaluating how well they prevent progression of chronic disease, with attention to long-term safety and real-world clinical benefit.

The site also supports important research in neurological disorders, including Alzheimer’s disease, multiple sclerosis, epilepsy, Parkinson’s disease, stroke, and multiple system atrophy. Many of these trials are aimed at improving symptom control, slowing decline, or testing approaches that may better support daily function and quality of life.

• Alzheimer’s disease and related behavioral or cognitive symptoms
• Multiple sclerosis and relapse prevention
• Epilepsy and reduction of seizure frequency
• Stroke recovery and functional outcomes

This area reflects a mix of treatment evaluation and symptom-focused research, with studies spanning cognition, mobility, and neurological recovery.

Clinical trials here cover a wide range of respiratory tract diseases and otolaryngologic conditions, including asthma, COPD, chronic rhinosinusitis, nasal polyps, and chronic spontaneous urticaria. The main goal is to evaluate new therapies that may improve breathing, reduce flare-ups, and ease persistent upper-airway symptoms.

• Severe asthma with ongoing symptoms despite standard care
• Chronic obstructive pulmonary disease and long-term safety studies
• Chronic rhinosinusitis with or without nasal polyps
• Chronic spontaneous urticaria and symptom relief

The research in this field is centered on improving control of chronic inflammatory airway and allergy-related diseases through better-targeted treatment options.

Unidade Local De Saude De Matosinhos E.P.E. is also involved in trials for immune-mediated and blood-related disorders, including chronic inflammatory demyelinating polyneuropathy, idiopathic systemic mastocytosis, thrombocytopenia, and immune system diseases. These studies are generally intended to assess whether new treatments can better control inflammation, reduce symptoms, or support standard therapy.

• Chronic inflammatory demyelinating polyneuropathy and disability-related outcomes
• Chemotherapy-induced thrombocytopenia in patients with cancer
• Indolent systemic mastocytosis and symptom management
• Immune-mediated disorders requiring long-term control

This therapeutic area combines supportive care research with studies of disease control, aiming to make treatment more effective and better tolerated.

The site contributes to studies in digestive system diseases, liver disease, and genitourinary cancer, reflecting a broad interest in both chronic metabolic liver conditions and solid tumors affecting the gastrointestinal and urinary systems. These trials are designed to test new therapies, improve disease control, and measure whether treatment can slow progression or reduce complications.

• Non-alcoholic steatohepatitis and liver fibrosis
• Gastroesophageal adenocarcinoma and related upper digestive cancers
• Colorectal cancer and other gastrointestinal malignancies
• Metastatic urothelial cancer and treatment effectiveness

The research activity in this area focuses on both cancer care and chronic liver disease, with an emphasis on meaningful clinical benefit and safer long-term management.

Several trials at the site address mental disorders, cognitive and behavioral symptoms, and other less common conditions. These include psychosis and agitation linked to Alzheimer’s disease, as well as studies in migraine, spasticity, and other neurological or functional disorders. The purpose is often to improve symptom relief, daily functioning, and treatment tolerability.

• Psychosis and agitation in Alzheimer’s disease
• Menstrual migraine prevention and symptom reduction
• Upper limb spasticity after stroke or brain injury
• Less common neurological and functional conditions requiring targeted care

This part of the portfolio shows the site’s interest in both common chronic illnesses and specialized conditions where better symptom control can make a major difference for patients.